Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CBG and Attention: A Double-Blind, Randomized, Placebo-Controlled Trial Examining the Effects of Cannabigerol on Indicators of Attention-Deficit/Hyperactivity Disorder

NCT06115603 is registered in ClinicalTrials.gov with University of Arkansas, Fayetteville as lead sponsor.

NCT NCT06115603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06115603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CBG and Attention: A Double-Blind, Randomized, Placebo-Controlled Trial Examining the Effects of Cannabigerol on Indicators of Attention-Deficit/Hyperactivity Disorder
Lead sponsor
University of Arkansas, Fayetteville
Phase
Phase 2
Overall status
Recruiting
Start date
December 14, 2024
Completion date
July 31, 2026
Enrollment
76 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

attention-deficit/hyperactivity disorder